- Conditions
- Congenital Heart Disease
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 10,399
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Respiratory Distress Syndrome In Premature Infants, Bronchopulmonary Dysplasia, Newborn Primary Sleep Apnea
- Interventions
- Seattle-PAP
- Device
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 6 Hours to 72 Hours
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 433 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- biologic sample preservation procedure
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 1,294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 292
- States / cities
- Fort Smith, Arkansas • Berkeley, California • Burbank, California + 192 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- Concizumab, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 8
- States / cities
- Torrance, California • Indianapolis, Indiana • Iowa City, Iowa + 5 more
- Conditions
- Surgical Complication, Paresthesia, Fracture, Nerve Injury, Nerve Entrapments, Mandibular Nerve Injuries, Mandibular Hypoplasia, Mandibular Retrognathism, Mandibular Hyperplasia, Mandibular Prognathism
- Interventions
- Sonopet ultrasonic saw, Reciprocating saw
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 45 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Hypophosphatasia
- Interventions
- asfotase alfa
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 24 Weeks to 42 Months
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Springfield, Missouri • Omaha, Nebraska + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- Hypertonic Saline, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Primary Insulin-like Growth Factor-1 Deficiency
- Interventions
- mecasermin [rDNA origin] injection
- Biological
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Basking Ridge, New Jersey
- Conditions
- Netherton Syndrome
- Interventions
- QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID
- Drug
- Lead sponsor
- Quoin Pharmaceuticals
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- High frequency chest wall oscillator
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Sanfilippo Syndrome, Mucopolysaccharidosis III
- Interventions
- Epidiolex, Placebo
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Primary Immune Deficiency Disorder
- Interventions
- Octagam 5%, Other marketed IVIG product
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 27
- States / cities
- Granada Hills, California • Irvine, California • Los Angeles, California + 22 more
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema or COPD
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 2 more
- Conditions
- Long QT Syndrome, Abnormalities, Drug-Induced
- Interventions
- Progesterone, Ibutilide
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Atopic Dermatitis
- Interventions
- Bodewell Calming Cream
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Tourette Syndrome
- Interventions
- Repetitive TMS
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- CAH - Congenital Adrenal Hyperplasia
- Interventions
- NBI-74788
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more
- Conditions
- Rett Syndrome, RTT
- Interventions
- GWP42003-P
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 11 more
- Conditions
- Alagille Syndrome, Pulmonary Artery Stenoses, Acquired Von Willebrand Disease
- Interventions
- Assessment for bleeding disorder with tailored post-operative care
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Heterotaxy Syndrome, Congenital Heart Defects
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2030
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana